AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide-Reference-Cited by-同舟云学术

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide

Published:2017-11 Issue:5 Volume:72 Page:828-834
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Seitz Anna Katharina,Thoene Silvia,Bietenbeck Andreas,Nawroth Roman,Tauber Robert,Thalgott Mark,Schmid Sebastian,Secci Ramona,Retz Margitta,Gschwend Jürgen E.,Ruland Jürgen,Winter Christof,Heck Matthias M.

Publisher

Elsevier BV

Subject

Urology

Reference28 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

2. Castration-resistant prostate cancer: from new pathophysiology to new treatment;Sridhar;Eur Urol,2014

3. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence;Coutinho;Endocr Relat Cancer,2016

4. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

5. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers;Frontiers in Oncology;2024-09-10

2. Androgen Receptor Splice Variant 7 in Asian Patients With Metastatic Castration-Resistant Prostate Cancer;JCO Precision Oncology;2024-06

3. Concept and feasibility of the Augsburg Longitudinal Plasma Study (ALPS) – a prospective trial for comprehensive liquid biopsy-based longitudinal monitoring of solid cancer patients;Journal of Laboratory Medicine;2024-04-19

4. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest;BMC Cancer;2024-04-16

5. Extracellular vesicles and prostate cancer management: a narrative review;Translational Andrology and Urology;2024-03